Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434743 | 0.83 | PTGS1 (0.53) | KMT2AP4HTMEPHX1MME | |
| SCHEMBL31189310 | 0.80 | PPARG (0.45) | KMT2AP4HTMMEN1HTT | |
| SCHEMBL29609793 | 0.80 | EPHX1 (0.71) | EGFRERBB2EPHX1PTGESSIGMAR1 | |
| SCHEMBL28605618 | 0.80 | EPHX1 (0.71) | EGFRERBB2EPHX1PTGESSIGMAR1 | |
| SCHEMBL3471743 | 0.80 | HCAR2 (0.47) | HCAR2EGFRERBB2PTGESSIGMAR1 | |
| SCHEMBL6006575 | 0.79 | KMT2A (0.49) | KMT2AFPR2 | |
| SCHEMBL27785183 | 0.78 | HCAR2 (0.46) | HCAR2EGFRERBB2PTGESSIGMAR1 | |
| SCHEMBL22264984 | 0.77 | KDM6B (0.54) | HCAR2EGFRERBB2PTGESSIGMAR1 | |
| SCHEMBL20702768 | 0.77 | KDM6B (0.54) | HCAR2EGFRERBB2PTGESSIGMAR1 | |
| SCHEMBL2030081 | 0.77 | KDM6B (0.54) | HCAR2EGFRERBB2PTGESSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088067-A1 | Novel amidine compounds for treating microbial infections | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088067-A1 | Novel amidine compounds for treating microbial infections | ARG1, ARG2, GSDMD | KMT2A 3066/4885P4HTM 897/4885CNR2 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.